Voting on treatment targets and outcomes
| Agreement* (%) | Accept | |
|---|---|---|
| Treatment targets | ||
| Serum urate level | 90 | Yes |
| Time to resolution of inflammation | 40 | No |
| Amount/reduction/absence of tophi (burden of deposition) | 90 | Yes |
| Pain reduction | 90 | Yes |
| Prevention/absence of attacks | 100 | Yes |
| Adherence to medication | 60 | No |
| Outcome | ||
| Clinical: Pain, joint count, number of attacks/year | 100 | Yes |
| Laboratory: Serum urate level, CRP, ESR, serum creatinine | 90 | Yes |
| Functional: SF-36 (physical component score) | 60 | No |
| Imaging: Radiographs (specific signs), ultrasound (tophi), dual energy CT (urate deposition) | 60 | No |
| PRO: QoL, SF-36, work status, productivity, work days off, absenteeism/presenteeism | 80 | Yes |
*10 members of the steering committee voted.
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; PRO, patient-reported outcomes; QoL, quality of life; SF-36, short-form 36.